High-risk illicit drug use Mental and Behavioural Disorders
Conditions
Interventions
The intervention tested was a prescription of diazepam at a maximum dose of 30 mg, and a fortnightly nurse session addressing: anxiety, sleep and pain management and harm reduction support to reduce h
Sponsors
University of Stirling
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. People in NHS drug treatment services who have achieved a stable dose of ORT (methadone or buprenorphine) 2. Have the capacity to provide informed consent 3. Experiencing ongoing risk of harm from street benzodiazepine use. ‘Risk of harm’ was defined as: an overdose event in the last 6 months in which a street benzodiazepine was implicated (from toxicology or clinical profile) and/or persistent self-report of daily street benzo use that is confirmed by toxicology screening and/or self-report of regular use of high doses/quantities of street benzodiazepines
Exclusion criteria
Exclusion criteria: 1. Co-occurring harmful alcohol use 2. Co-occurring harmful stimulant use 3. Pregnancy 4. Participation in any other research study 5. Diagnosed serious mental illness or severe cognitive impairment that clinical staff consider poses a risk to safety (of patient or staff) 6. Non-English speaking 7. People who do not have the capacity to provide informed consent 8. ‘Harmful’ alcohol or stimulant use was use at a level in which it was the dominant problem for that individual
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Use of illicit benzodiazepines measured using self-report and oral fluid testing monthly during the study | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Cognitive ability assessed using Addenbrooke's Cognitive Evaluation (ACE III) at baseline & follow-up (6 months) 2. Quality of life assessed using EQ5D-5L monthly during the study 3. Anxiety assessed using General Anxiety Disorder (GAD-7) at baseline & follow-up (6 months) 4. Depression assessed using Patient Health Questionnaire-9 (PHQ-9) at baseline & follow-up (6 months) 5. Self-assessed substance use recovery assessed using SURE questionnaire at baseline & follow-up (6 months) 6. Economic evaluation using NHS service use questionnaire completed monthly during the study 7. Satisfaction with professional care assessed using Consultation and Relational Empathy Measure (CARE) at follow-up (6 months) | — |
Countries
Scotland, United Kingdom
Contacts
Public ContactCatriona Matheson
Outcome results
None listed